Two new studies entitled “Systematic identification of signaling pathways with potential to confer anticancer drug resistance” and “RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis” identified new players and their downstream pathways that participate in the acquisition of resistance to current anti-cancer therapeutics by cancer cells. Both studies were published in the journal Science Signaling.
MRV Research
Novogen announces positive preclinical results for melanoma treatment
Novogen Limited has announced that TRXE-009, which was originally developed for treating brain cancers, was also found to be highly active against melanoma in preclinical studies.
MMP 2014 Community Questions Report regarding access to clinical trials for rural vs metropolitan patients.
Thank you to everyone that participated in our survey. You were obviously passionate about the ‘rural vs metro access to clinical trials’ topic as 216 of you participated. Your contribution…
Read More Researchers Identify Protein Involved In Melanoma Metastasis Into The Lung
In a recent study titled “Role of Chitinase 3-like-1 and Semaphorin 7A in Pulmonary Melanoma Metastasis”, published in Cancer Research, a team of researchers from Brown and Yale University found that a protein named chitinase 3-like-1 (CHI3L1) plays a central role in the spread of malignant melanoma to the lungs.